News & Events

• September 13, 2019
  Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure

• September 9, 2019 - September 10, 2019
  

  Solutions to Drug Development Challenges Workshop: Utilizing Quantitative Approaches, Data Sharing, and Novel Biomarkers

    Title Presenter Presentation Link Introduction Dr. John-Michael Sauer (C-Path) Keynote Address Dr. Joseph Scheeren (C-Path)   Welcoming Remarks Dr. Janet Woodcock (US FDA) Session 2: Benefits of DDT progression to regulatory acceptance Moderators: Dr. Inish O’Doherty (C-Path) and Dr. Ameeta Parekh (US FDA) 2.1 A perspective on the history and evolution of drug development...
• August 14, 2019
  Conrado et al. 2019 Towards Regulatory Endorsement

  Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
• August 12, 2019
  

  C-Path’s Critical Path for Parkinson’s Consortium (CPP) is pleased to welcome Linda L. Restifo, MD, PhD, as a Visiting Scientist

  C-Path’s Critical Path for Parkinson’s Consortium (CPP) is pleased to welcome Linda L. Restifo, MD, PhD, as a Visiting Scientist. Currently a Professor of Neurology at the University of Arizona College of Medicine – Tucson, Dr. Restifo is a neurogeneticist with broad interests in translational medicine. She will be using her expertise to help CPP...
• August 7, 2019
  

  Funded by FDA, C-Path and NORD to Launch Rare Disease Data and Analytics Platform

  C-Path and NORD Rare Disease Cures Accelerator Data Analytics Platform Launch, Tuesday, Sept. 17, Bethesda, MD

  C-Path and the National Organization for Rare Disorders® will host a meeting to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative agreement through the U.S. Food and Drug Administration, the goal of the platform is to accelerate the movement of therapies from bench to bedside for rare diseases. Register here.